A new drug for optic neuritis and myelitis spectrum diseases
Part of Brain & nervous system, Immune system & allergy clinical trials.
This trial tests a new drug called ripeltumab in people with neuromyelitis optica spectrum disorder (NMOSD), a condition that causes inflammation of the optic nerve and spinal cord. It aims to reduce relapses by targeting the immune system.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with NMOSD.
- You have had at least 1 NMOSD attack needing treatment in the past year, or 2 attacks in the past 2 years.
- You are not pregnant and agree to use effective contraception during the study and for 6 months after.
- You have not used certain immune-suppressing drugs or treatments in the past few months (the study team will help you check).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called Ripertamab to see if it can help children and young adults with nephrotic syndrome who keep relapsing or need steroids to stay in remission. It aims to offer a treatment option that may reduce relapses.
This trial tests a new drug called Ripertamab for people with CIDP, a nerve condition causing weakness. The study will see if it can improve symptoms compared to standard therapies.
This trial tests a new medicine, ripertamab, for people with generalized myasthenia gravis (gMG). It aims to see if targeting certain immune cells can help reduce symptoms like muscle weakness.
This trial tests an antibody treatment for people having a neuromyelitis optica (NMO) relapse. It may reduce nerve damage from inflammation during an acute attack.
This study tests a new medicine called ravulizumab (an infusion) to reduce relapses in people with neuromyelitis optica spectrum disorder (NMOSD), a rare condition affecting the optic nerve and spinal cord. The trial is specifically enrolling adults in China who have had recent disease activity.
This trial compares several medications to see which works best for NMOSD, an autoimmune disease that can cause vision loss and paralysis. You must have a specific antibody (AQP4-IgG) to join.
Hear when a new Neuromyelitis Optica Spectrum Disease (NMOSD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.